Both the Food and Drug Administration (FDA) and GlaxoSmithKline (GSK) have prepared pre-recorded presentations for the August 31, 2020, Pulmonary-Allergy Drugs Advisory Committee meeting. These pre-recorded presentations will be viewed by the committee prior to the meeting and **will not be replayed on meeting day.**

The recordings of the presentations can be found at the following addresses:

**FDA Presentations (listed in viewing order):**

1. Overview of the Clinical Program by Robert Busch, MD: [https://collaboration.fda.gov/pahbij6skgp/](https://collaboration.fda.gov/pahbij6skgp/)
2. Statistical Review of Efficacy by Susan Duke, MS, MS: [https://collaboration.fda.gov/pg9zrco44jvg/](https://collaboration.fda.gov/pg9zrco44jvg/)
3. Clinical Considerations by Robert Busch, MD: [https://collaboration.fda.gov/pgeiy291ky81/](https://collaboration.fda.gov/pgeiy291ky81/)
4. Charge to the Committee by Banu Karimi-Shah, MD: [https://collaboration.fda.gov/pv5tf7xclu8b/](https://collaboration.fda.gov/pv5tf7xclu8b/)

**GSK Presentations (listed in viewing order):**

1. Introduction by C. Elaine Jones, PhD: [https://collaboration.fda.gov/pfomwq6qtit3/](https://collaboration.fda.gov/pfomwq6qtit3/)
2. Relevant Clinical Data by David Lipson, MD: [https://collaboration.fda.gov/pjgk3p5osrr3/](https://collaboration.fda.gov/pjgk3p5osrr3/)
3. Clinical Perspective by Robert A. Wise, MD: [https://collaboration.fda.gov/pluwsua2ypu3/](https://collaboration.fda.gov/pluwsua2ypu3/)
4. Summary and Conclusion by C. Elaine Jones, PhD: [https://collaboration.fda.gov/phxgq076ngcb/](https://collaboration.fda.gov/phxgq076ngcb/)

Your internet browser may require a plugin to playback these presentations. If your browser does not already have it installed, you may be prompted to download and install it.

The slides and transcripts of these pre-recorded presentations can be found at: [https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-august-31-2020-meeting-pulmonary-allergy-drugs-advisory](https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-august-31-2020-meeting-pulmonary-allergy-drugs-advisory)